title: Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis.
abstract: Our aim was to study the effect of lower airway infection on clinical parameters, pulmonary function tests, and inflammation in clinically stable infants and young children with cystic fibrosis (CF). To accomplish this goal, a prospective cohort of screened CF patients under 4 years of age were studied, using elective anesthesia and intubation for: passive respiratory mechanics (single breath occlusion passive deflation) and lung volumes (nitrogen washout), under neuromuscular blockade; and bronchoalveolar lavage (BAL) of 3 main bronchi for cytology, cytokine interleukin (IL)-8, and quantitative microbiology. There were 22 children studied, with a mean age of 23.2 months (6.7-44 months). A greater relative risk of lower airway pathogens was associated with prior respiratory admission (3.60, 95% confidence interval [CI] 2.87-4.51), history of asthma (1.75, 95% CI 1.52-2.03), and chronic symptoms (1.50, 95% CI 1.23-1.83), especially wheeze (1.88, 95% CI 1.61-2.19). Lower respiratory pathogens (> or = 10 cfu/ml BAL) were found in 14 out of 22, and greater than 10(5) cfu/ml in 8 out of 22 subjects. The level of pathogens in BAL (log10 cfu/ml) explained 78% of the variability in percent neutrophils and 34% of the variability in IL-8 levels. Pathogen level also correlated with pulmonary function tests of specific respiratory system compliance (r -0.49, p = 0.02) and functional residual capacity over total lung capacity (r 0.49, p = 0.03). We conclude that the presence of pathogens in the lower airways correlated with levels of inflammation, respiratory system compliance, and degree of air trapping.
authors.affiliation: Department of Respiratory Medicine and Intensive Care Unit, Sydney Children's Hospital, Sydney, New South Wales, Australia. CarolynD@adhb.govt.nz
authors.forename: Carolyn J
authors.initials: CJ
authors.lastname: Dakin
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Numa
authors.forename: He
authors.initials: H
authors.lastname: Wang
authors.forename: John R
authors.initials: JR
authors.lastname: Morton
authors.forename: Calypso C
authors.initials: CC
authors.lastname: Vertzyas
authors.forename: Richard L
authors.initials: RL
authors.lastname: Henry
mesh_terms: D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology / Q000382:microbiology; D002452:Cell Count; D002675:Child, Preschool; D015331:Cohort Studies; D003550:Cystic Fibrosis / Q000382:microbiology / Q000473:pathology / Q000503:physiopathology*; D005260:Female; D006801:Humans; D007223:Infant; D007249:Inflammation; D018836:Inflammation Mediators / Q000032:analysis; D016753:Interleukin-10 / Q000032:analysis; D016209:Interleukin-8 / Q000032:analysis; D008168:Lung / Q000473:pathology*; D008297:Male; D011446:Prospective Studies; D011552:Pseudomonas Infections / Q000150:complications* / Q000503:physiopathology; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification; D015656:Respiratory Mechanics; D012141:Respiratory Tract Infections / Q000150:complications* / Q000503:physiopathology
chemical_list: D018836:Inflammation Mediators; D016209:Interleukin-8; D016753:Interleukin-10